证券研究报告 | 公司点评 gszqdatemark 2026 03 27 年 月 日 公司业绩阶段性承压，多项业务调整稳步推进。公司 2025 年前三季度实 现营业收入 25.97 亿元（yoy-7.34%），实现归母净利润 1.42 亿元（yoy- 17.19%），毛利率同比-0.38pcts 至 51.47%。 化妆品板块中颐莲及珂谧表现良好，瑷尔博士仍处于调整期。2025 年前 三季度化妆品板块营业收入 15.69 亿元，同比下降 8.17%，毛利率为 61.24%。其中，颐莲品牌继续保持增长，前三季度实现收入 7.86 亿元， 同比增长 19.50%，其中喷雾品线实现销售收入 6.64 亿元，同比增长 28%； 瑷尔博士品牌前三季度实现收入 6.46 亿元，第三季度同比降幅有所收窄， 品牌变革稳步推进；珂谧品牌前三季度实现收入 7719 万元，第二季度环 比增长 82%，第三季度环比增长 138%，保持高速增长态势，线上渠道完 成从抖音单渠道到全渠道布局，构建"自播+达播"矩阵，线下渠道纵深 发展，战略推进与线下机构的深度绑定与赋能。其中，珂谧与新华网联合 打造的 2 场专场活动 GMV 突破 30 ...

同比+5.1%，跑赢社零大盘1.4pct、较2024年显著回暖，其中25H1、25H2分别同比增长2.9%、7.3%， 下半年行业增速改善明显 2 / CONTENTS 3 / 01 02 03 04 05 4 / 01 美妆大盘：化妆品增速回暖跑赢社零，线上天猫回暖、抖音降速 • 2025年化妆品社零同比增长5.1%跑赢社零，线上天猫、抖音平台增速收敛。据国家统计局，2025年限额以上单位化妆品累 零售额4653亿元，同比+5.1%，跑赢社零大盘1.4pct、较2024年显著回暖，其中25H1、25H2分别同比增长2.9%、7.3%， 下半年行业增速改善明显。重点线上平台方面，据久谦数据，2025年天猫、抖音美妆大盘分别同比+2%、+16%，抖音依 然为主要增量渠道，但2025Q3起线上渠道格局逐渐生变，25Q3天猫、抖音美妆个护品类分别同比+8%、+8%，两核心平 台增速收敛，且这一趋势延续至Q4，我们判断主要因天猫平台在即时零售的拉动下增速呈回暖态势，而抖音随着规模增 大、达播趋弱，增速有所放缓，电商渠道格局趋于稳定。 01 品类趋势：彩妆、个护品类增长强于护肤，个护新品牌破局 • 2025年彩妆、个护 ...

Core Viewpoint - The Chinese cosmetics industry is undergoing a significant "ingredient revolution," with recombinant collagen emerging as a core force in reconstructing product value systems. The key question remains whether large molecular recombinant collagen can effectively penetrate the skin barrier to reach its target sites [3][4]. Group 1: Technological Breakthroughs - The "transdermal collagen" technology developed by Kemi, a brand under Furuida Bio Co., has been recognized as reaching an internationally leading level by the China Light Industry Federation [4][20]. - Kemi's technology has achieved a 27.5 times increase in transdermal efficiency, addressing the industry-wide challenge of large molecular penetration [6][10]. - The core issue of collagen efficacy lies in the dilemma of activity versus permeability, with traditional methods reducing molecular size at the cost of biological activity [7][11]. Group 2: Innovative Solutions - Kemi's solution involves a systematic technology called "transdermal collagen," which enhances the penetration ability of large molecular collagen through genetic engineering [8][11]. - The "transmembrane peptide" acts as a "biological engine," enabling large molecular collagen to actively penetrate cell membranes, thus overcoming traditional passive diffusion limitations [8][10]. - The "super glass collagen microsphere" technology ensures stable presence and sustained release of active collagen within the skin, significantly improving penetration rates [10][11]. Group 3: Market Validation - Kemi's flagship product, the "Kemi Recombinant Collagen Anti-Wrinkle Essence," combines the two proprietary delivery technologies, resulting in measurable skincare effects [12][14]. - In just eight months, the transdermal collagen essence achieved sales exceeding 23 million units, topping various e-commerce beauty charts [14][15]. - The brand's marketing strategy focuses on building trust through deep communication and collaboration with authoritative media, enhancing consumer perception of its technological innovations [15][16]. Group 4: Industry Impact and Standards - Kemi has transitioned from a "dark horse" to a "definer" in the industry, actively participating in the formulation of industry standards, including the first group standard for measuring the penetration efficacy of recombinant collagen [20][23]. - The establishment of these standards marks a shift from vague marketing claims to quantifiable scientific parameters, promoting a new phase of verifiable efficacy in the industry [24][25]. - Kemi's approach signifies a broader industry shift from marketing-driven strategies to technology-driven value creation, setting a benchmark for future developments in the cosmetics sector [25].

Investment Rating - The investment rating for the retail industry is "Positive" (maintained) [1] Core Insights - The report highlights the strong performance of domestic brands during the 38 promotional event, with significant sales figures and consumer demand for effective skincare products [23][25] - The report emphasizes the importance of emotional consumption themes and recommends high-quality companies in high-growth sectors [6][30][31] Summary by Sections Retail and Social Services Market Review - The retail and social services indices reported declines of 3.91% and 3.63% respectively during the week of March 2 to March 6, 2026 [5][15] - Year-to-date, the retail index has decreased by 6.82%, while the social services index has increased by 3.01% [15][16] Industry Dynamics - Domestic brands performed well during the 38 promotional event, with leading brands like Proya achieving significant sales [23] - The report notes that the skincare product category is seeing strong demand, particularly for effective and functional products [23][25] Investment Recommendations - Investment focus areas include: - **Gold and Jewelry**: Recommend brands with differentiated product offerings such as Laopuhuang and Chaohongji [6][30] - **Offline Retail**: Highlight companies adapting to trends like Yonghui Supermarket and Aiyingshi [6][30] - **Cosmetics**: Focus on brands that meet emotional value and safety innovation, recommending brands like Maogeping and Proya [6][31] - **Medical Aesthetics**: Suggest companies with differentiated products and expanding chains, such as Meilitiantian Medical Health and Aimeike [6][31] Company Performance Highlights - **Shangmei Co.**: Expected revenue of 9.1-9.2 billion yuan for 2025, with a year-on-year growth of 34.0%-35.4% [27] - **Zhou Dafu**: Achieved a retail value increase of 17.8% year-on-year in Q3 2026 [32] - **Yonghui Supermarket**: Anticipated revenue decline but undergoing significant operational adjustments [32]

Investment Rating - The investment rating for the retail industry is "Positive" (maintained) [1] Core Insights - The report highlights the strong performance of domestic brands during the 38 promotional event, with significant sales figures and consumer demand for effective skincare products [23][25] - The report emphasizes the importance of emotional consumption themes and recommends high-quality companies in high-growth sectors [6][30][31] Summary by Sections Retail and Social Services Market Review - The retail and social services indices reported declines of 3.91% and 3.63% respectively during the week of March 2 to March 6, 2026, ranking 25th and 23rd among 31 primary industries [5][15] - Year-to-date, the retail index has decreased by 6.82%, while the social services index has increased by 3.01% [12][15] Industry Dynamics - The 38 promotional event saw domestic brands excel, with significant sales figures reported from live streaming platforms [23][25] - Key brands such as Pechoin and Betainy led in product selection and sales performance during the promotional period [23][24] Investment Recommendations - Investment focus areas include: - Gold and jewelry brands with differentiated product offerings, recommending companies like Laopuhuangjin and Chaohongji [6][30] - Offline retail companies adapting to market changes, recommending Yonghui Supermarket and Aiyingshi [6][30] - Domestic beauty brands that emphasize emotional value and innovative ingredients, recommending Maogeping and Shangmei [6][31] - Medical aesthetics firms with differentiated products, recommending Meilitiantian and Aimeike [6][31] Company Performance Highlights - Shangmei Co. is projected to achieve revenues of 9.1-9.2 billion yuan, a year-on-year increase of 34.0%-35.4%, with net profits expected to reach 1.14-1.16 billion yuan, up 41.9%-44.4% [27][29] - Zhou Dafu reported a retail value increase of 17.8% year-on-year for FY2026Q3, driven by product structure optimization [32]

Summary of Conference Call Notes Company and Industry Overview - The conference call discusses the performance and outlook of various brands under the company, including 瑷尔博士 (Aier Doctor), 颐莲 (Yilian), and 珂谧 (Kemi) within the cosmetics and healthcare industry [2][3][4]. Key Points and Arguments Brand Performance and Growth - 瑷尔博士 is undergoing a brand adjustment due to pricing issues, expected to recover by January 2026, leading to a return to high growth [2][4]. - 颐莲 is projected to achieve double-digit growth in 2025, driven by the successful upgrade of its spray line and the introduction of the "嘭润" series [2][4]. - 珂谧 aims for sales exceeding 100 million in 2025, with a strategic shift towards the "益生菌 287" series and the high-margin 王浆酸 series, which boasts an 85% gross margin [2][4]. Raw Materials and Pharmaceutical Segment - The raw materials segment, particularly hyaluronic acid, is experiencing high demand and rising prices, which will support performance in 2025-2026 [2][5]. - The pharmaceutical segment is minimally affected by centralized procurement policies, with ongoing exploration of new product paths, including health supplements [5]. Channel Strategy - The company is shifting its focus from Tmall to Douyin (TikTok), with single-channel sales accounting for over 30% [2][6]. - 瑷尔博士 has established 500-600 skin research institutes through a franchise model, enhancing brand reach and profitability [2][6]. Market Trends and Challenges - The overall sales performance during the "三八" (March 8) promotion was satisfactory, but the industry faces challenges such as prolonged promotional periods and rising costs of influencer marketing [7][8]. - The company is adapting to changes in consumer behavior and marketing efficiency, particularly in the context of Douyin's rising prominence [8]. Product Development and Innovation - The company has a robust pipeline for new products in 2026, focusing on upgrading existing lines and introducing new offerings [10][12]. - The 王浆酸 series is expected to perform well, with a focus on educating consumers about its benefits and leveraging content-driven marketing strategies [11][12]. Financial Outlook and Strategic Initiatives - The company anticipates a return to stable growth in 2026, following adjustments made in 2025 [3][16]. - There are ongoing discussions regarding stock incentives and potential mergers, with no definitive timelines provided [15][16]. Additional Important Content - The company is exploring overseas expansion, though short-term contributions to revenue are expected to be limited as they focus on establishing compliance and registration [14][15]. - The medical aesthetics segment is being developed with a focus on compliance and safety, leveraging existing sales teams to penetrate medical institutions [12][13]. This summary encapsulates the key insights from the conference call, highlighting the company's strategic direction, brand performance, market challenges, and future growth prospects.

Group 1 - The company, Furuida (600223), has responded to investor inquiries on its interactive platform regarding the proceeds from the divestiture of its real estate business [1] - Following the receipt of the divestiture proceeds, the company plans to strategically allocate the funds according to its corporate strategy [1]

（文章来源：每日经济新闻） 福瑞达（600223.SH）2月11日在投资者互动平台表示，目前公司重组人源化三型胶原蛋白三类医疗器械 申请生物学检验正在进行中。 每经AI快讯，有投资者在投资者互动平台提问：公司重组人源化三型胶原蛋白三类医疗器械进度如 何？ ...

Core Viewpoint - The report from Huayuan Securities indicates that Furida has streamlined its operations by divesting its real estate business, leading to stable growth in its cosmetics segment. The company is building core competitive advantages through a combination of products, research and development, and distribution channels [1] Group 1: Business Strategy - The company is actively promoting innovations in synthetic biological materials and terminal pharmaceuticals, as well as beauty applications, while continuously increasing R&D investment to strengthen its core business competitiveness [1] - The divestiture of the real estate business allows the company to focus on its core operations, enhancing its growth potential in the cosmetics and pharmaceutical sectors [1] Group 2: Market Position and Comparables - Comparable companies in the domestic market, such as Proya, Shanghai Jahwa, and Huaxi Biological, are expected to have an average PE ratio of 28 times by 2026 according to Wind consensus forecasts [1] - Given the company's strategic focus on optimizing its product mix and deepening its multi-channel layout in the cosmetics business, a positive long-term performance outlook is anticipated [1] Group 3: Investment Rating - The report initiates coverage of the company with a "Buy" rating, reflecting optimism about its mid-to-long-term performance following the strategic changes [1]

Investment Rating - The report assigns a "Buy" rating for the company, indicating a positive outlook following the divestiture of its real estate business and steady growth in the cosmetics segment [5][42]. Core Insights - The company has transitioned its main business focus to cosmetics and pharmaceuticals after divesting its real estate operations in 2023. The cosmetics segment has shown resilience, contributing over 52.8% of total revenue [10][41]. - The company is leveraging a "product + R&D + channel" strategy to build competitive advantages, focusing on marketing synergies, innovation in product development, and a comprehensive online and offline sales network [8][30][34]. - Revenue projections for 2025-2027 are estimated at RMB 38.1 billion, RMB 39.3 billion, and RMB 43.0 billion, with corresponding growth rates of -4.3%, +3.1%, and +9.5% respectively. Net profit is expected to reach RMB 2.4 billion, RMB 2.7 billion, and RMB 3.1 billion during the same period [9][41]. Summary by Sections Market Performance - The closing price of the stock is RMB 7.36, with a total market capitalization of RMB 7,481.95 million and a circulating market value of RMB 7,481.95 million [3]. Financial Data - The company reported a gross margin of 46.49% in 2023, a significant increase of 21.84 percentage points from the previous year, primarily due to the strategic shift away from low-margin real estate operations [21]. Revenue and Profit Forecast - The company anticipates a decline in revenue for 2023, followed by a gradual recovery, with net profit growth projected at +0.2%, +8.8%, and +15.3% for the years 2025 to 2027 [9][41]. Business Segments - The cosmetics segment is expected to see revenue growth of -5%, +6%, and +14% from 2025 to 2027, while the pharmaceutical segment is projected to grow at -5%, -3%, and +5% during the same period [10][41]. - The raw materials and additives segment is forecasted to grow steadily, with revenue increases of +3%, +4%, and +5% from 2025 to 2027 [10]. Competitive Positioning - The company is positioned favorably against comparable domestic brands, with a projected price-to-earnings (P/E) ratio of 28 times for 2026, aligning with industry averages [42]. Marketing and R&D Strategy - The company has invested significantly in R&D, with a budget of RMB 1.16 billion for the first three quarters of 2025, representing a research expense ratio of 4.47% [30]. - New product launches and marketing initiatives are focused on enhancing brand visibility and consumer engagement across various channels, including e-commerce and physical retail [28][34]. Sales Channels - The cosmetics segment's revenue is heavily driven by online sales, contributing 84.2% of total revenue, while offline sales account for 15.8% [34]. - The company is expanding its presence in both online and offline markets, establishing flagship stores on major e-commerce platforms and increasing the number of physical retail locations [34].